Share on LinkedInShare on LinkedIn

ARTICLE · 26 JULY 2017

Revisions To The Senate Better Care Reconciliation Act

Holland & Knight
Explore more from Holland & Knight

Senate Majority Leader Mitch McConnell this weekend delayed plans to hold a procedural vote this week to move forward with the Senate's Better Care Reconciliation Act (BCRA) healthcare reform bill...

United StatesFood, Drugs, Healthcare, Life Sciences
Miranda A. Franco
Miranda A. Franco
Robert Bradner
Robert Bradner
Lisa Hawke
Lisa Hawke
Author LinkedIn connections

Robert Bradner and Lisa Tofil are Partners and Miranda Franco is a Senior Policy Advisor in the Washington D.C. office

Senate Majority Leader Mitch McConnell this weekend delayed plans to hold a procedural vote this week to move forward with the Senate's Better Care Reconciliation Act (BCRA) healthcare reform bill while Sen. John McCain (R-AZ) recovers from surgery to remove a blood clot from above his left eye. The Congressional Budget Office also is no longer expected to release a revised score of the bill. Read more information about the healthcare reform bill revisions in this memorandum authored by Holland & Knight's Healthcare and Life Sciences Team.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters

Read more about

Related Comparative Guides

See more popular content from

Article

FDA Seeks Public Feedback On Regulatory Approach For Generative AI-Enabled Medical Devices

The U.S. Food and Drug Administration has released a discussion paper outlining its initial framework for regulating generative AI-enabled medical devices, proposing a two-axis risk assessment approach and a novel competency-based premarket evaluation system. With public comments due by October 19, 2026, this represents a critical opportunity for device manufacturers and stakeholders to shape the regulatory landscape for this transformative technology.
United StatesFood, Drugs, Healthcare, Life Sciences
Katten
Katten
Article

California OHCA Issues Final Regulations Implementing Expanded Health Care Transaction Review Requirements For Private Equity, Hedge Funds, And MSOs

On Friday, California Office of Health Care Affordability (“OHCA”) published proposed final regulations that implement a 2026 law that significantly expanded OHCA’s review authority over health care transactions involving private equity (“PE”) groups, hedge funds, and management services organizations (“MSOs”). Stakeholders involved in California health care transactions should re-assess whether their ongoing or contemplated transactions are implicated by these regulations, because newly covered transactions will need to comply with the 90-day advance notice requirement established in the original OHCA regulations.
United StatesFood, Drugs, Healthcare, Life Sciences
Simpson Thacher & Bartlett LLP
Simpson Thacher & Bartlett LLP
Article

FDA Holds Landmark Public Hearing On The Future Therapeutic Use Of Psychedelic Drugs

The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.
United StatesFood, Drugs, Healthcare, Life Sciences
Foley Hoag LLP
Foley Hoag LLP
Article

FDA Balances Peptide Policy With Enforcement Against Unlawful Peptide Sellers

Over the past year, industry has had a front row seat as the Food and Drug Administration (“FDA” or the “Agency”) decides just how much leeway it wants to afford the manufacture, marketing, and sale of peptide products, and just where it wants to draw the line. Despite the recent decision of FDA’s Pharmacy Compounding Advisory Committee (“PCAC”) to recommend a number of peptides for inclusion on the 503A bulks list process — a move that represents a potentially more permissive stance toward peptide regulation, at least in terms of what can and cannot be compounded under 503A...
United StatesFood, Drugs, Healthcare, Life Sciences
Sheppard
Sheppard
Article

CMS Offers Guidance As Scrutiny Rises Over ABA Therapy In Medicaid

Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy.
United StatesFood, Drugs, Healthcare, Life Sciences
Crowell & Moring LLP
Crowell & Moring LLP